← Kelly Casteel, MD

From R-CHOP to CAR-T: The DLBCL Timeline

An interactive, clinician-facing chronicle of the trials that built modern DLBCL care — from the CHOP and R‑CHOP chemoimmunotherapy backbone through the anti-CD79b and anti-CD19 antibody–drug conjugates, CD19 CAR‑T, and CD20×CD3 bispecifics. A curative first line that resisted change for two decades while the relapsed/refractory landscape was rebuilt. Click any drug to trace its Phase 1→3→approval lineage; click a trial for arms, endpoints, results, and FDA/EMA milestones.

Data verified against ClinicalTrials.gov & primary literature · last reviewed Jul 2026

View

Drug class

Trial phase

Ph 1 Ph 2 Ph 3

Status

Approved Investigational Withdrawn / failed

Activity

Ongoing only

NCCN

In NCCN v3.2026 Category 1 only

Reference

Solid outline = approved Dashed outline = investigational Dashed rose = withdrawn / failed Pulsing dot = ongoing trial ✓badge = FDA / EMA approved NCCN category badge (1 / 2A / biomarker) Ambient curve = rising survival as approvals accrue

Scroll horizontally → · click a drug node to open its trial lineage

NCCN preferred regimens by line of therapy

Derived from NCCN Clinical Practice Guidelines in Oncology — B-Cell Lymphomas (DLBCL), Version 3.2026 (Mar 2026)

Preference tiers (Preferred / Other Recommended / Useful in certain circumstances) and Categories of Evidence (1, 2A, 2B) are summarised for reference and attributed to NCCN. This is not a reproduction of the guideline; consult the authoritative, current version at nccn.org. Click a drug chip to jump to that agent’s trial lineage. Selinexor's listing is expected to be removed in an upcoming version following its 2026 FDA withdrawal.